PRECISION BIOSCIENCES INC (DTIL) earnings date
Mar 18, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 20 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 3, 2026 | before open | 34 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | before open | 35 | 8-K |
| Q4 FY2025 | Thu, Mar 12, 2026 | before open | 71 | 8-K |
| Q3 FY2025 | Mon, Nov 3, 2025 | before open | 34 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Thu, May 15, 2025 | before open | 45 | 8-K |
| Q4 FY2024 | Wed, Mar 26, 2025 | before open | 85 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update - PBGENE-HBV late-breaking oral presentation for ELIMINATE-B trial at AASLD's The Liver Meeting® 2026 on November 8; data abstract scheduled for release November 5 - - Dosed first patient with PBGENE-DMD at Arkansas Children's Hospital in the Phase 1/2 FUNCTION-DMD study; initial safety data targeted for year-end 2026 - - Cash balance of $108 million including cash, cash equivalents and restricted cash as of September 30, 2026, expected to provide runway through 2028 and enable" exhibit |
| Q3 FY2026 | "“We remain on track to deliver data updates from both programs by year end, supported by a financial position that provides expected runway through 2028 and through key clinical inflection points.”" exhibit |
| Q3 FY2026 | "Initial safety data are targeted for year-end 2026, with efficacy data at distinct timepoints expected to follow in H1 and H2 2027." exhibit |
| Q3 FY2026 | "The Company expects that existing cash and cash equivalents, continued fiscal and operating discipline, and availability of Precision’s at-the-market facility will fund the Company’s cash runway through 2028." exhibit |
| Q3 FY2026 | "Based on its expected cash runway, Precision projects it is sufficiently capitalized to achieve key PBGENE-HBV and PBGENE-DMD clinical data milestones through 2028." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining - - In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV - - Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial - - Next PBGENE-H" exhibit |
| Q2 FY2026 | "Precision continues its work with global investigators for next phase study design and expects to provide additional updates on the ELIMINATE-B trial progress by the end of 2026." exhibit |
| Q2 FY2026 | "The study is actively recruiting patients with initial safety data expected for year-end 2026." exhibit |
| Q2 FY2026 | "The Company expects that existing cash and cash equivalents, continued fiscal and operating discipline, and availability of Precision’s at-the-market facility will fund the Company’s cash runway through 2028." exhibit |
| Q2 FY2026 | "Based on its expected cash runway, Precision believes it is sufficiently capitalized to achieve PBGENE-HBV and PBGENE-DMD data milestones through 2028." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/DTIL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/DTIL
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/DTIL/"><img src="https://veritasdata.dev/embed/DTIL.svg" alt="DTIL earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/DTIL/)
Script
<script async src="https://veritasdata.dev/embed/DTIL.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/DTIL"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.